Literature DB >> 14084698

BLOOD COAGULATION AND PLATELET ECONOMY IN SUBJECTS WITH PRIMARY GOUT.

J F MUSTARD, E A MURPHY, M A OGRYZLO, H A SMYTHE.   

Abstract

Previous studies have suggested that there is an increased incidence of degenerative vascular disease in patients with gout and an increased rate of turnover of blood platelets in patients and animals with atherosclerosis. A disturbed uric acid metabolism and "secondary" gout have long been known to occur with bone marrow diseases. A study of platelet economy and blood clotting factors in subjects with primary gout was therefore undertaken.Twenty-two male subjects with gout but with no clinical evidence of vascular disease were studied. Half of these had a negative family history for vascular disease and half had less fortunate ancestors. The most striking differences were found when gouty patients with a negative family history for vascular disease were compared with similar control subjects. The mean platelet half-life was 2.85 days in the gouty subjects and 3.74 days in the controls. The mean platelet turnover (number/c.mm./day) was 58,750 in gouty subjects, 42,370 in controls. Platelet adhesiveness and plasma thromboplastic activity were correspondingly increased in the gouty subjects. Control subjects with a positive family history all showed relatively active clotting system and platelet turnover, similar to the values found in atherosclerotic subjects. The data indicated that there is increased platelet destruction and production in some patients with primary gout. The relation between this anomaly and the vascular disease, and disturbed urate metabolism in gouty subjects, remains to be investigated.

Entities:  

Keywords:  ARTERIOSCLEROSIS; BLOOD COAGULATION TESTS; BLOOD PLATELETS; GOUT; METABOLISM; PROTHROMBIN TIME; STATISTICS; URIC ACID

Mesh:

Substances:

Year:  1963        PMID: 14084698      PMCID: PMC1922159     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  26 in total

1.  Hyperuricemia; relationship to hypercholesteremia and acute myocardial infarction.

Authors:  P M KOHN; G B PROZAN
Journal:  J Am Med Assoc       Date:  1959-08-15

2.  A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraminosalicylic acid in man.

Authors:  J W JENNE; F M MACDONALD; E MENDOZA
Journal:  Am Rev Respir Dis       Date:  1961-09

3.  Dicumarol therapy. Some effects on platelets and their relationship to clotting tests.

Authors:  E A MURPHY; J F MUSTARD
Journal:  Circ Res       Date:  1960-11       Impact factor: 17.367

4.  Intermediary purine metabolism and the metabolic defects of gout.

Authors:  J B WYNGAARDEN
Journal:  Metabolism       Date:  1957-05       Impact factor: 8.694

5.  Clinical implications of isoniazid blood levels in pulmonary tuberculosis.

Authors:  R S MITCHELL; J C BELL
Journal:  N Engl J Med       Date:  1957-11-28       Impact factor: 91.245

6.  Leukaemia and related conditions and the blood-uric-acid.

Authors:  R A HICKLING
Journal:  Lancet       Date:  1958-01-25       Impact factor: 79.321

7.  Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate.

Authors:  J A COHEN; C H LEEKSMA
Journal:  J Clin Invest       Date:  1956-09       Impact factor: 14.808

8.  The pathogenesis of gout.

Authors:  S J THANNHAUSER
Journal:  Metabolism       Date:  1956-09       Impact factor: 8.694

9.  Inhibition of isoniazid acetylation in vitro and vivo.

Authors:  W JOHNSON; G CORTE
Journal:  Proc Soc Exp Biol Med       Date:  1956-06

10.  Primary and secondary gout.

Authors:  A B GUTMAN
Journal:  Ann Intern Med       Date:  1953-11       Impact factor: 25.391

View more
  15 in total

Review 1.  Serum uric acid is not an independent risk factor for coronary heart disease.

Authors:  S G Wannamethee
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.

Authors:  M Nakashima; T Uematsu; K Kosuge; M Kanamaru
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Release of platelet constituents by monosodium urate crystals.

Authors:  M H Ginsberg; F Kozin; M O'Malley; D J McCarty
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

4.  [The BBC study. Applied epidemiology of ischemic heart diseases].

Authors:  S Heyden
Journal:  Arch Kreislaufforsch       Date:  1967-06

5.  Relationship between hyperuricemia and other cardiovascular disease risk factors among adult males in Taiwan.

Authors:  N F Chu; D J Wang; S H Liou; S M Shieh
Journal:  Eur J Epidemiol       Date:  2000-01       Impact factor: 8.082

6.  Serum uric Acid in smokers.

Authors:  Bassam E Hanna; Jamal M Hamed; Luma M Touhala
Journal:  Oman Med J       Date:  2008-10

Review 7.  Could uric acid have a pathogenic role in pre-eclampsia?

Authors:  Annabel C Martin; Mark A Brown
Journal:  Nat Rev Nephrol       Date:  2010-10-19       Impact factor: 28.314

8.  Stroke Risk in Patients with Gout: A Nationwide Retrospective Cohort Study in Taiwan.

Authors:  Ping-Han Tsai; Chang-Fu Kuo; Lai-Chu See; Pei-Ru Li; Jung-Sheng Chen; Wen-Yi Tseng
Journal:  J Clin Med       Date:  2022-06-29       Impact factor: 4.964

9.  THE EFFECT OF SULFINPYRAZONE (ANTURAN) ON PLATELET ECONOMY AND BLOOD COAGULATION IN MAN.

Authors:  H A SMYTHE; M A OGRYZLO; E A MURPHY; J F MUSTARD
Journal:  Can Med Assoc J       Date:  1965-04-10       Impact factor: 8.262

10.  Artificial cold air increases the cardiovascular risks in spontaneously hypertensive rats.

Authors:  Bin Luo; Shuyu Zhang; Shoucun Ma; Ji Zhou; Baojian Wang
Journal:  Int J Environ Res Public Health       Date:  2012-09-04       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.